Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 12913 to 1304 of 1304 entries
Sorted by: Best Match Show Resources per page
Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy.

Diabetes research and clinical practice

Lupușoru G, Ailincăi I, Sorohan BM, Andronesi A, Achim C, Micu G, Caragheorgheopol A, Manda D, Lupușoru M, Ismail G.
PMID: 34728182
Diabetes Res Clin Pract. 2021 Dec;182:109116. doi: 10.1016/j.diabres.2021.109116. Epub 2021 Oct 30.

AIMS: To investigate serum soluble form of urokinase-type plasminogen activator receptor (suPAR) in patients with diabetic kidney disease (DKD) and biopsy-proven diabetic nephropathy (DN), its correlation with histological parameters and its capacity as a biomarker for renal impairment severity.METHODS:...

Cite
Lupușoru G, Ailincăi I, Sorohan BM, et al. Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy. Diabetes Res Clin Pract. 2021;182:109116doi: 10.1016/j.diabres.2021.109116.
Lupușoru, G., Ailincăi, I., Sorohan, B. M., Andronesi, A., Achim, C., Micu, G., Caragheorgheopol, A., Manda, D., Lupușoru, M., & Ismail, G. (2021). Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy. Diabetes research and clinical practice, 182109116. https://doi.org/10.1016/j.diabres.2021.109116
Lupușoru, Gabriela, et al. "Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy." Diabetes research and clinical practice vol. 182 (2021): 109116. doi: https://doi.org/10.1016/j.diabres.2021.109116
Lupușoru G, Ailincăi I, Sorohan BM, Andronesi A, Achim C, Micu G, Caragheorgheopol A, Manda D, Lupușoru M, Ismail G. Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy. Diabetes Res Clin Pract. 2021 Dec;182:109116. doi: 10.1016/j.diabres.2021.109116. Epub 2021 Oct 30. PMID: 34728182.
Copy Download .nbib Format: NLM
Precision nutrition for gut microbiome and diabetes research: Application of nutritional n-of-1 clinical trials.

Journal of diabetes

Zheng JS, Ordovás JM.
PMID: 34453774
J Diabetes. 2021 Dec;13(12):1059-1061. doi: 10.1111/1753-0407.13220. Epub 2021 Aug 28.

No abstract available.

Cite
Zheng JS, Ordovás JM. Precision nutrition for gut microbiome and diabetes research: Application of nutritional n-of-1 clinical trials. J Diabetes. 2021;13(12):1059-1061doi: 10.1111/1753-0407.13220.
Zheng, J. S., & Ordovás, J. M. (2021). Precision nutrition for gut microbiome and diabetes research: Application of nutritional n-of-1 clinical trials. Journal of diabetes, 13(12), 1059-1061. https://doi.org/10.1111/1753-0407.13220
Zheng, Ju-Sheng, and Ordovás, José M. "Precision nutrition for gut microbiome and diabetes research: Application of nutritional n-of-1 clinical trials." Journal of diabetes vol. 13,12 (2021): 1059-1061. doi: https://doi.org/10.1111/1753-0407.13220
Zheng JS, Ordovás JM. Precision nutrition for gut microbiome and diabetes research: Application of nutritional n-of-1 clinical trials. J Diabetes. 2021 Dec;13(12):1059-1061. doi: 10.1111/1753-0407.13220. Epub 2021 Aug 28. PMID: 34453774.
Copy Download .nbib Format: NLM
Corrigendum to 'A novel indicator predicts 2019 novel coronavirus infection in subjects with diabetes'. [Diab. Res. Clin. Practice 166 (2020) 108294].

Diabetes research and clinical practice

Ozder A, Salduz ZIY, Durdu B, Okyaltirik F, Cakirca M.
PMID: 34763904
Diabetes Res Clin Pract. 2021 Dec;182:109111. doi: 10.1016/j.diabres.2021.109111. Epub 2021 Nov 09.

No abstract available.

Cite
Ozder A, Salduz ZIY, Durdu B, et al. Corrigendum to 'A novel indicator predicts 2019 novel coronavirus infection in subjects with diabetes'. [Diab. Res. Clin. Practice 166 (2020) 108294]. Diabetes Res Clin Pract. 2021;182:109111doi: 10.1016/j.diabres.2021.109111.
Ozder, A., Salduz, Z. I. Y., Durdu, B., Okyaltirik, F., & Cakirca, M. (2021). Corrigendum to 'A novel indicator predicts 2019 novel coronavirus infection in subjects with diabetes'. [Diab. Res. Clin. Practice 166 (2020) 108294]. Diabetes research and clinical practice, 182109111. https://doi.org/10.1016/j.diabres.2021.109111
Ozder, Aclan, et al. "Corrigendum to 'A novel indicator predicts 2019 novel coronavirus infection in subjects with diabetes'. [Diab. Res. Clin. Practice 166 (2020) 108294]." Diabetes research and clinical practice vol. 182 (2021): 109111. doi: https://doi.org/10.1016/j.diabres.2021.109111
Ozder A, Salduz ZIY, Durdu B, Okyaltirik F, Cakirca M. Corrigendum to 'A novel indicator predicts 2019 novel coronavirus infection in subjects with diabetes'. [Diab. Res. Clin. Practice 166 (2020) 108294]. Diabetes Res Clin Pract. 2021 Dec;182:109111. doi: 10.1016/j.diabres.2021.109111. Epub 2021 Nov 09. PMID: 34763904; PMCID: PMC8576051.
Copy Download .nbib Format: NLM
Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial.

Diabetes research and clinical practice

Rooney MR, Wang D, McEvoy JW, Juraschek SP, Chalmers J, Woodward M, Selvin E.
PMID: 34800609
Diabetes Res Clin Pract. 2021 Dec;182:109148. doi: 10.1016/j.diabres.2021.109148. Epub 2021 Nov 17.

We found that 1,5-anhydroglucitol-a marker of glucose excursions-was not independently associated with subclinical cardiac damage, nor with vascular outcomes, in the ADVANCE Trial. High-sensitivity cardiac troponin T and N-terminal pro-b-type natriuretic peptide provided better prognostic information regarding vascular risk...

Cite
Rooney MR, Wang D, McEvoy JW, et al. Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial. Diabetes Res Clin Pract. 2021;182:109148doi: 10.1016/j.diabres.2021.109148.
Rooney, M. R., Wang, D., McEvoy, J. W., Juraschek, S. P., Chalmers, J., Woodward, M., & Selvin, E. (2021). Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial. Diabetes research and clinical practice, 182109148. https://doi.org/10.1016/j.diabres.2021.109148
Rooney, Mary R, et al. "Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial." Diabetes research and clinical practice vol. 182 (2021): 109148. doi: https://doi.org/10.1016/j.diabres.2021.109148
Rooney MR, Wang D, McEvoy JW, Juraschek SP, Chalmers J, Woodward M, Selvin E. Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial. Diabetes Res Clin Pract. 2021 Dec;182:109148. doi: 10.1016/j.diabres.2021.109148. Epub 2021 Nov 17. PMID: 34800609.
Copy Download .nbib Format: NLM
Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice.

Journal of diabetes research

Peng H, Mu P, Li H, Lin S, Lin C, Lin K, Liu K, Zeng W, Zeng L.
PMID: 34917687
J Diabetes Res. 2021 Dec 07;2021:9943344. doi: 10.1155/2021/9943344. eCollection 2021.

Insulin treatment was confirmed to reduce insulin resistance, but the underlying mechanism remains unknown. Caveolin-1 (Cav-1) is a functional protein of the membrane lipid rafts, known as caveolae, and is widely expressed in mammalian adipose tissue. There is increasing...

Cite
Peng H, Mu P, Li H, et al. Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice. J Diabetes Res. 2021;2021:9943344doi: 10.1155/2021/9943344.
Peng, H., Mu, P., Li, H., Lin, S., Lin, C., Lin, K., Liu, K., Zeng, W., & Zeng, L. (2021). Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice. Journal of diabetes research, 20219943344. https://doi.org/10.1155/2021/9943344
Peng, Hangya, et al. "Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice." Journal of diabetes research vol. 2021 (2021): 9943344. doi: https://doi.org/10.1155/2021/9943344
Peng H, Mu P, Li H, Lin S, Lin C, Lin K, Liu K, Zeng W, Zeng L. Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice. J Diabetes Res. 2021 Dec 07;2021:9943344. doi: 10.1155/2021/9943344. eCollection 2021. PMID: 34917687; PMCID: PMC8670926.
Copy Download .nbib Format: NLM
Differential HLA Association of GAD65 and IA2 Autoantibodies in North Indian Type 1 Diabetes Patients.

Journal of diabetes research

Chuzho N, Kumar N, Mishra N, Tandon N, Kanga U, Kaur G, Singh P, Mishra G, Sharma S, Mehra NK.
PMID: 34988229
J Diabetes Res. 2021 Dec 27;2021:4012893. doi: 10.1155/2021/4012893. eCollection 2021.

The human leucocyte antigen (HLA) association with type 1 diabetes (T1D) is well known but there are limited studies investigating the association between

Cite
Chuzho N, Kumar N, Mishra N, et al. Differential HLA Association of GAD65 and IA2 Autoantibodies in North Indian Type 1 Diabetes Patients. J Diabetes Res. 2021;2021:4012893doi: 10.1155/2021/4012893.
Chuzho, N., Kumar, N., Mishra, N., Tandon, N., Kanga, U., Kaur, G., Singh, P., Mishra, G., Sharma, S., & Mehra, N. K. (2021). Differential HLA Association of GAD65 and IA2 Autoantibodies in North Indian Type 1 Diabetes Patients. Journal of diabetes research, 20214012893. https://doi.org/10.1155/2021/4012893
Chuzho, Neihenuo, et al. "Differential HLA Association of GAD65 and IA2 Autoantibodies in North Indian Type 1 Diabetes Patients." Journal of diabetes research vol. 2021 (2021): 4012893. doi: https://doi.org/10.1155/2021/4012893
Chuzho N, Kumar N, Mishra N, Tandon N, Kanga U, Kaur G, Singh P, Mishra G, Sharma S, Mehra NK. Differential HLA Association of GAD65 and IA2 Autoantibodies in North Indian Type 1 Diabetes Patients. J Diabetes Res. 2021 Dec 27;2021:4012893. doi: 10.1155/2021/4012893. eCollection 2021. PMID: 34988229; PMCID: PMC8723877.
Copy Download .nbib Format: NLM
Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Battelino T, Mauricio D.
PMID: 34455574
Diabetes Ther. 2021 Oct;12(10):2635-2644. doi: 10.1007/s13300-021-01143-6. Epub 2021 Aug 29.

No abstract available.

Cite
Battelino T, Mauricio D. Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results. Diabetes Ther. 2021;12(10):2635-2644doi: 10.1007/s13300-021-01143-6.
Battelino, T., & Mauricio, D. (2021). Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results. Diabetes therapy : research, treatment and education of diabetes and related disorders, 12(10), 2635-2644. https://doi.org/10.1007/s13300-021-01143-6
Battelino, Tadej, and Mauricio, Didac. "Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 12,10 (2021): 2635-2644. doi: https://doi.org/10.1007/s13300-021-01143-6
Battelino T, Mauricio D. Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results. Diabetes Ther. 2021 Oct;12(10):2635-2644. doi: 10.1007/s13300-021-01143-6. Epub 2021 Aug 29. PMID: 34455574; PMCID: PMC8479020.
Copy Download .nbib Format: NLM
Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue.

de Groot M, Fisher L.
UIID-AD: 2695
2011;11:503-10. doi: 10.1007/s11892-011-0231-x.

In the context of a diabetes epidemic and health care workforce crisis in the United States, a national dialogue is needed to identify the pathways and mechanisms for training a cohort of behavioral diabetes researchers and clinicians. Over the...

Cite
de Groot M, Fisher L. Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue. 2011;11:503-10doi: 10.1007/s11892-011-0231-x.
de Groot, M., & Fisher, L. (2011). Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue. 11503-10. https://doi.org/10.1007/s11892-011-0231-x
de Groot, M, and Fisher, L. "Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue." vol. 11 (2011): 503-10. doi: https://doi.org/10.1007/s11892-011-0231-x
de Groot M, Fisher L. Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue. 2011;11:503-10. doi: 10.1007/s11892-011-0231-x. UIID-AD: 2695.
Copy Download .nbib Format: NLM
Showing 12913 to 1304 of 1304 entries